Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD
Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven
Verified email at - Homepage
Cited by
Cited by
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ...
The Lancet 387 (10027), 1540-1550, 2016
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ...
Nature 515 (7528), 563-567, 2014
The biology and management of non-small cell lung cancer
RS Herbst, D Morgensztern, C Boshoff
Nature 553 (7689), 446-454, 2018
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non–small cell lung cancer: a randomized trial
MG Kris, RB Natale, RS Herbst, TJ Lynch Jr, D Prager, CP Belani, ...
Jama 290 (16), 2149-2158, 2003
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non …
DH Johnson, L Fehrenbacher, WF Novotny, RS Herbst, JJ Nemunaitis, ...
Journal of Clinical Oncology 22 (11), 2184-2191, 2004
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2
RS Herbst, G Giaccone, JH Schiller, RB Natale, V Miller, C Manegold, ...
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
G Giaccone, RS Herbst, C Manegold, GV Scagliotti, R Rosell, V Miller, ...
Longitudinal analyses reveal immunological misfiring in severe COVID-19
C Lucas, P Wong, J Klein, TBR Castro, J Silva, M Sundaram, ...
Nature 584 (7821), 463-469, 2020
Review of epidermal growth factor receptor biology
RS Herbst
International Journal of Radiation Oncology* Biology* Physics 59 (2), S21-S26, 2004
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet, 2020
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with chemotherapy …
DA Eberhard, BE Johnson, LC Amler, AD Goddard, SL Heldens, ...
Journal of clinical oncology 23 (25), 5900-5909, 2005
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer
RS Herbst, D Prager, R Hermann, L Fehrenbacher, BE Johnson, ...
Journal of clinical oncology 23 (25), 5892-5899, 2005
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...
New England Journal of Medicine, 2020
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
RS Herbst, G Giaccone, F de Marinis, N Reinmuth, A Vergnenegre, ...
New England Journal of Medicine 383 (14), 1328-1339, 2020
Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
K Shedden, JMG Taylor, SA Enkemann, MS Tsao, TJ Yeatman, ...
Nature medicine 14 (8), 822, 2008
The BATTLE trial: personalizing therapy for lung cancer
ES Kim, RS Herbst, II Wistuba, JJ Lee, GR Blumenschein, A Tsao, ...
Cancer discovery 1 (1), 44-53, 2011
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
SB Goldberg, SN Gettinger, A Mahajan, AC Chiang, RS Herbst, M Sznol, ...
The lancet oncology 17 (7), 976-983, 2016
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study …
GD Demetri, M Kris, J Wade, L Degos, D Cella
Journal of Clinical Oncology 16 (10), 3412-3425, 1998
An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor …
LA Byers, L Diao, J Wang, P Saintigny, L Girard, M Peyton, L Shen, Y Fan, ...
Clinical cancer research 19 (1), 279-290, 2013
Antiemetics: American Society of Clinical Oncology clinical practice guideline update
E Basch, AA Prestrud, PJ Hesketh, MG Kris, PC Feyer, MR Somerfield, ...
Journal of Clinical Oncology 29 (31), 4189, 2011
The system can't perform the operation now. Try again later.
Articles 1–20